District versus academic hospitals: differences in the clinical characteristics of patients with atrial fibrillation without valvular heart disease treated with oral anticoagulants

摘要

Introduction Atrial fibrillation (AF) is the most common cardiac arrhythmia with a significant risk of morbidity and mortality. Non–vitamin K antagonist oral anticoagulants are the?first?line drugs in stroke prevention in patients with AF. Oral anticoagulant (OAC) therapy may differ between medical c enters. Objectives We compared the clinical characteristics of AF patients treated with OAC in a district and an academic hospital. Patients and methods We analyzed 3528 patients from the multicenter retrospective CRAFT study: 2666 patients from the?academic hospital and 862 patients from the?district hospital. Their baseline clinical characteristics were compared. Results Patients treated in the district hospital were older (mean [SD] age, 73.9 [10.3] years vs 66.0 [13.4] years; P 0.001) and more likely female (49.1% vs 37.4%; P 0.001). Patients treated in the academic hospital more frequently had paroxysmal AF, while those in the district hospital, permanent AF. The latter group was also more likely to have comorbidities and a higher frequency of previous bleeding episodes or anemia. The?groups did not differ regarding kidney function. In both groups, patients were significantly more likely to be on rivaroxaban than on dabigatran. The group treated in the district hospital were at higher risk of thromboembolic events than the other gruop (mean [SD] CHA2DS2VASc score, 4.6 [1.7] vs 3.05 [2.0]; P 0.001), as well as of hemorrhagic events (mean [SD] HASBLED score, 0.6 [0.7] vs 0.4 [0.6]; P 0.001). Conclusions Patients with AF treated with OACs in the district and academic hospitals have different clinical characteristics. Patients treated in the district hospital were older, had more comorbidities, more frequently had permanent AF, and were at higher risk of thromboembolic and bleeding events than patients treated in the?academic hospital.